Where Industry Meets Innovation

  • Contact Us
  • sign in Sign In
  • Sign in with certificate
mit campus

Resources

Search Videos

  • View All
  • ILP Videos
  • MIT Faculty Shorts
  • Tech-TV
  • Startup Exchange

Conferences Videos

  • 4/8 Autonomy
    04.08.20
  • 3/18 Innovations in Management
    03.18.20
  • 12/10 Productivity in Biopharma
    12.10.19
  • 11/13 Research and Development
    11.13.19
  • 11/8 Paris Symposium
    11.08.19
  • 11/7 Madrid Symposium
    11.07.19

Featured Videos

RECENT VIDEOS

7 Results | Last Page
 

12.10.2019
33 mins
ILP Video

The Future of Drug R&D: How Biomedical Scientists Will Square the Circle

Bernard Munos
Senior Fellow, FasterCures
Founder, InnoThink Center for Research in Biomedical Innovation
That will cover both challenges that seem intractable today and advances that offer a pathway towards more innovation, cheaper and faster innovation, as well as a shift from incremental to exponential innovation.
Read More

12.10.2019
28 mins
ILP Video

PhysioMimetics: From Organoids to Organs - on - Chips, through Systems Biology

Linda Griffith
School of Engineering Professor of Teaching Innovation
Professor of Biological and Mechanical Engineering
Director, Center for Gynepathology Research (CGR)
MIT Department of Biological Engineering
?Mice are not little people? ? a refrain becoming louder as the strengths and weaknesses of animal models of human disease become more apparent. At the same time, three emerging approaches are headed toward integration: powerful systems biology analysis of cell-cell and intracellular signaling networks in patient-derived samples; 3D tissue engineered models of human organ systems, often made from stem cells; and micro-fluidic and meso-fluidic devices that enable living systems to be sustained, perturbed and analyzed for weeks in culture. This talk will highlight the integration of these rapidly moving fields to understand difficult clinical problems, with an emphasis on translating academic discoveries into practical use. Technical challenges in modeling complex diseases with ?organs on chips? approaches include the need for relatively large tissue masses and organ-organ cross talk to capture systemic effects, as well as new ways of thinking about scaling to capture multiple different functionalities from drug clearance to cytokine signaling crosstalk. Examples in gynecology , metabolic diseases and other chronic inflammatory conditions will be highlighted.
Read More

12.10.2019
32 mins
ILP Video

Fast and Modular Manufacturing Systems for Biopharmaceuticals in Vaccines

J Christopher Love
Professor of Chemical Engineering
Associate Member, Broad Institute
Graduate Admissions Officer (Chem-E)
MIT Department of Chemical Engineering
Recombinant biopharmaceuticals and vaccines represent a significant class of therapeutics and preventions. While the industry has established efficient platformed processes for the production of monoclonal antibodies at multi-ton scales, the improved precision of therapeutic indications and expanding molecular designs (such as bispecific antibodies, nanobodies, and others) add new challenges for the timely and cost-effective production of emerging therapeutic concepts. This talk will present an integrated approach to biomanufacturing that combines automated end-to-end production and purification along with a fast and engineering-friendly alternative host to enable a flexible platform for next-generation manufacturing. Examples in both biopharmaceuticals and vaccines will be presented.
Read More

12.10.2019
57 mins
ILP Video

Startup Exchange-Lighting Talks

Rebecca Xiong
Gregory Ryslik
Kevin O'Handley
Atray Dixit
Andrew A. Radin
Anne Kim
Matthew Osman
Siping Wang
- Celsius Therapeutics: AI & single cell genomics for autoimmune & immune oncology therapy
- Javelin Biotech: Complex in vitro models & AI to optimize lead selection
- Coral Genomics: Scalable functional human genomics for drug development
- twoXAR: Pharmaceutical company utilizing AI for drug discovery
- Secure AI Labs: AI security & data privacy to accelerate life science analytics
- Legit: AI-powered research assistant for life sciences
- TetraScience: Streamlined R&D lab workflows with data integration
- Nirmidas Biotech: IR fluorescence science for molecular diagnostics, in vivo imaging, & therapeutics
- ConquerX: Multi-biomarker electro-chemical cancer diagnostic
- Resolute Bio: Discovery platform optimizing peptide therapeutics
- Mytide: Industrializing peptide manufacturing for iterative drug discovery
Read More

12.10.2019
32 mins
ILP Video

Estimating and Predicting Clinical Trial Success Rates: A Data Science Approach

Andrew W. Lo
Charles E and Susan T Harris Professor of Finance
Director, Laboratory for Financial Engineering
MIT Sloan School of Management
All investors require some understanding of the potential risk and reward of a given venture before they?re willing to invest, and the less they know about it, the less capital will be available. This is especially true with biomedical assets in which the risks and rewards are equally outsized and hard to evaluate. Therefore, a prerequisite for addressing the so-called ?Valley of Death? in early-stage biomedical R&D funding is better risk analytics. In this talk, Prof. Lo will describe his latest research on estimating historical probabilities of success for clinical trials and then applying machine-learning techniques to predict future success rates across a variety of drug/indication pairs. With more accurate assessments of these success probabilities, capital can be deployed more efficiently and at lower cost, thereby bringing greater amounts of capital into the biopharma industry at a time when capital is needed most.
Read More

12.10.2019
26 mins
ILP Video

Using Systems Biology and Computational Approaches to Identify New Drug Targets and Chemotherapy Combinations

Michael Yaffe
Director, MIT Center for Precision Cancer Medicine
David H. Koch Professor of Science
Director of Clinical Outreach
Prof. of Biology and Biological Engineering
Senior Associate Member, Broad Institute
Protein kinase signaling pathways are high-value targets for drug development efforts in oncology and inflammatory diseases. Many clinically useful drugs that inhibit these pathways function as ATP mimetics that compete for non-covalent binding to the kinase active site. The conserved nature of the ATP-binding pocket, however, often results in a lack of kinase specificity, or leads to low affinity pharmacophores for kinases that have shallow ATP-binding clefts. These difficulties have stimulated interest in developing drugs that target allosteric regulatory sites on kinases, as well as identifying drug combinations that enhance the on-target efficacy of ATP-based inhibitors by co-targeting additional pathways components. A priori identification of druggable allosteric sites on kinases has been challenging, however, as has been elucidating mechanisms of drug synergy that would direct co-targeting efforts. In this talk I will discuss two systems-based combined experimental/computational efforts that address these shortfalls. We have developed comparative coupling analysis as a kinase family-specific method to identify conserved ?sectors? within protein kinases that mediate catalysis, substrate specificity, and allosteric regulation. We have found that the allosteric sectors revealed by this method closely map to known sites of allosteric inhibitor binding, suggesting that the method can accurately identify and nominate allosteric sites on kinases for targeting in cases where no current allosteric inhibitors have yet been developed. Next, to identify mechanisms of drug synergy, we developed VISAGE ? Volumetric Interrogation of Synergy and Gene Set Enrichment, and used this computational approach to identify disruption of microtubule assembly as a target that specifically synergizes with ATP competitive inhibitors of Plk1 in a cancer-specific manner.
Read More

12.10.2019
30 mins
ILP Video

Paying for Drugs in a World of Expensive Treatments for Rare Disease

Jonathan Gruber
Ford Professor of Economics
MIT Department of Economics
We are entering a new world of very effective, but very expensive, drug treatments for rare disease. How should society think about pricing these treatments? Are there financial models that can help spread the costs and make them more affordable? And what does this suggest for a new role for government-financed Research and Development?
Read More

MIT Partners

  • mit video
    MITVideo aggregates and curates video produced by the Institute's offices, laboratories, centers and administration.
  • tech tv
    MIT Tech TV is the video-sharing site for the MIT community.